

# Thailand

Population 2018

69 million

Estimates of TB burden <sup>o</sup> , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	106 (81–136)	153 (116–195)
HIV-positive TB incidence	11 (8.2–14)	15 (12–20)
MDR/RR-TB incidence <sup>oo</sup>	4 (2.3–6.1)	5.7 (3.3–8.8)
HIV-negative TB mortality	9.2 (6.9–12)	13 (9.9–17)
HIV-positive TB mortality	2.3 (1.7–3)	3.3 (2.4–4.4)

## Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	2.3% (1.3–3.4)
Previously treated cases	24% (18–31)

## TB case notifications, 2018

Total new and relapse	85 029
- % tested with rapid diagnostics at time of diagnosis	19%
- % with known HIV status	79%
- % pulmonary	85%
- % bacteriologically confirmed <sup>ooo</sup>	59%
- % children aged 0–14 years	1%
- % women	31%
- % men	68%
Total cases notified	86 949

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	80% (63–110)
--	--------------

## TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2018	11% (8–15)
--	------------

## TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	6 780	10%
- on antiretroviral therapy	5 391	80%

## Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance <sup>ooo</sup>	
- New cases	30%
- Previously treated cases	62%
Laboratory-confirmed cases*	MDR/RR-TB: 1 312, XDR-TB: 29
Patients started on treatment**	MDR/RR-TB: 910, XDR-TB: 21
MDR/RR-TB cases tested for resistance to second-line drugs	665

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	84%	80 160
Previously treated cases, excluding relapse, registered in 2017	55%	1 848
HIV-positive TB cases registered in 2017	73%	7 130
MDR/RR-TB cases started on second-line treatment in 2016	61%	952
XDR-TB cases started on second-line treatment in 2016	75%	8

## TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	6.4% (5.9–7.1)

## TB financing, 2019

National TB budget (US\$ millions)	27
Funding source: 88% domestic, 12% international, 0% unfunded	

<sup>o</sup> Ranges represent uncertainty intervals

<sup>oo</sup> MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


<sup>ooo</sup> Calculated for pulmonary cases only

\* Includes cases with unknown previous TB treatment history

\*\* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




Legend:  
■ Total TB incidence  
■ New and relapse TB cases notified  
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:  
■ HIV-negative TB mortality

## Notified cases by age group and sex, 2018




Legend:  
■ Females ■ Males  Incidence

## Treatment success rate (%)



Legend:  
■ New and relapse  
■ Retreatment, excluding relapse  
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

## Total budget (US\$ millions)



Legend:  
■ Unfunded  
■ Funded internationally  
■ Funded domestically